Plasmid DNA remains a critical enabling technology for gene editing, serving as donor templates across ex vivo and in vivo therapeutic platforms. But as programs advance, the limitations of conventional plasmid design are becoming harder to ignore. This session explores how construct design influences performance beyond the edit, impacting efficiency, safety, and expression durability. It will focus on how a smaller, more efficient vector backbone can improve consistency and support more reliable downstream outcomes—providing insight into the Nanoplasmid™ design approach.